Cell Therapy vs Gene Therapy — Rare Disease Deal Terms Comparison
Market Analysis
In rare disease, Cell Therapy and Gene Therapy represent two of the most actively transacted modalities. At Phase 2, Cell Therapy deals carry a median total deal value of $2.5B with $456M upfront, compared to $1.6B total value and $285M upfront for Gene Therapy. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Cell Therapy development milestones average $441M versus $283M for Gene Therapy. Commercial milestones are $1.1B for Cell Therapy and $682M for Gene Therapy. Royalty rates range from 8.2%-16.4% for Cell Therapy and 7.8%-15.6% for Gene Therapy.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Cell Therapy and Gene Therapy deal terms compare in rare disease?
Which modality commands higher royalty rates: Cell Therapy or Gene Therapy?
How do milestone structures differ between Cell Therapy and Gene Therapy?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.
Start CalculatingNeed the full deal landscape?
The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.